

A Review of Ankylosing Spondylitis

Hannah Owen

A Senior Thesis submitted in partial fulfillment  
of the requirements for graduation  
in the Honors Program  
Liberty University  
Spring 2017

## Abstract

Ankylosing spondylitis (AS) is a systemic autoimmune disorder that induces ankylosis of the spine (fusion of the vertebrae at their various joints) and inflammatory arthritis of peripheral joints among other symptoms. Overexpression of cytokines, the presence of genetic mutations not exclusive to the human leucocyte antigen (HLA)-B27 region, and environmental factors all have large roles in the progressive development of AS.

Although a definitive pathology continues to be sought after, researchers believe the adaptive immune system in AS patients attacks fibrocartilaginous entheses (supportive connective tissue between bone and attached structures like tendon, ligament, and fascia). AS markedly reduces proper systemic functioning in several areas of human physiology, including the musculoskeletal, cardiovascular, neurological, psychiatric, and reproductive systems in both genders. A diagnosis for this disease requires the presentation of several qualifying symptoms, namely chronic inflammatory back pain, peripheral joint arthritis, enthesitis (inflammation of the enthesis not associated with a joint), uveitis (inflammation of the uvea or inner eye layer), and positive response to non-steroidal anti-inflammatory drugs (NSAIDs), with radiological support through x-ray or magnetic resonance imaging (MRI). Upon an AS diagnosis, patients should engage in healthy lifestyle changes, non-impact exercise, and taking NSAIDs as the first pharmacological treatment. Symptoms unresolved by NSAIDs are then treated with disease modifying antirheumatic drugs (DMARDs) and/or biologic medications like a monoclonal TNF $\alpha$  antibody to prevent further disease progression. Continued research to understand the association between AS

and interleukin (IL)-17/IL-23 is needed for development of additional biologic treatments.

### A Review of Ankylosing Spondylitis

Ankylosing spondylitis (AS) is a complex auto-immune disorder with a 0.5-0.9% global prevalence that affects males two to three times more often than female patients (Jamshidi et al., 2014; Sieper, Braun, Rudwaleit, Boonen, & Zink, 2002). Ankylosis of the vertebrae and surrounding connective tissues, especially within the sacroiliac joints, leads to reduced mobility of the spine and rib cage. AS characteristically develops in early adulthood between the ages of 20 and 40 years-old and tends to worsen with age as the disease progresses (Calin, 1984). While a human leukocyte antigen (HLA)-B27 gene mutation often corresponds with an AS diagnosis, the etiology of the disease remains unknown. A distinctive pathogenesis is also unknown. The disease's correlation with HLA-B27, increased IgA antibody levels in mucus, and chronic inflammatory histology suggest AS develops from excessive immune mediated responses, but the exact mechanism of action is still to be determined (Westerveld, Verlaan, & Oner, 2009). This review serves as an additional resource to educate primary care physicians and others about the theorized pathology, physiology, and treatments associated with ankylosing spondylitis.

### **Pathology**


Enthesitis is often considered a hallmark of AS, possibly the root condition leading to ankylosis. The condition refers to inflammation of an inserted structure of connective tissue onto a bone, such as a ligament, tendon, or sheath of fascia. Fibrocartilage of the bone at the enthesis site appears to be targeted by autoimmune responses in AS (Sieper et al., 2002). Bone marrow biopsies from AS patients (AS<sup>+</sup> bone

marrow) showed evidence of edema (swelling due to increased presence of fluid) with elevated levels of Cluster of Differentiation 8+ (CD8+) cytotoxic T cells (kill infected or cancerous self cells), CD3+ T cells, CD4+ helper T cells (activate innate immunity cells like macrophages), and CD20+ B cells. These findings indicated an active immune response occurred within sterile bone marrow of AS patients, meaning no exogenous pathogens such as viral or bacterial infections initiated this auto-immune response. The immune cells present appeared to actively break down entheses fibrocartilage surrounding vertebral facet joints with their associated ribs and neighboring vertebrae as well as the entheses' articulating bone tissue, which was also comprised of fibrocartilage. Other areas of noted damage included fibrocartilaginous entheses about peripheral joints, like the hip and knee, and entheses along the shafts of long bones, such as the insertion of the tibialis anterior muscle onto the tibia (bone that makes up the shin). Research of the pathology of AS finds that inflammatory destruction not only affects the entheses of the spine, but also damages the annulus fibrosus (fibrous exterior portion of the intervertebral disc that connects one vertebral body to another via ligamentous structures seen in Figure 1) which fuses neighboring vertebral bodies over time (Sieper et al., 2002).



*Figure 1.* Illustration of human spine with identified compartments of the intervertebral disc and the spinal cord (sourced from <http://www.bionebio.com/startling-top-human-anatomy-and-physiology-of-the-spine-pictures/pulposus-anatomy-and-physiology-of-the-spine-spinal-cord-spinal-nerves-nucleus-intervertebral-disc-annulus-fibrosus-pinal-cord-is-located/> under Pulposus Anatomy and Physiology of the Spine).

Regarding the vertebral column, an influx of mononuclear immune cells directly correlates with osteitis (inflammation of the bone) and edema within AS<sup>+</sup> bone marrow, thus indicating an autoimmune response on the non-infected bone marrow. T cells most likely initiate a response after activation by a self-antigen of cartilaginous descent to ultimately induce the lysis of cartilaginous support cells through an inflammatory immune response. This lysis damages healthy cartilaginous tissue to form an ankylosed or “bamboo” spine, seen in Figure 2. This outcome is classic for an AS patient after ossification occurs (Sieper et al., 2002).



*Figure 2.* Radiographic image of an ankylosed spine, also known as “bamboo spine.” The arrows indicate marginal osteophytes, ossified outgrowths of the degenerated cartilage between vertebral joints shown. (Image sourced from Dr. Donald Corenman of the Steadman Clinic.)

Within Jethwa and Bowness’s 2016 research, three mechanisms of AS spinal tissue degradation were postulated regarding the vague relationship between the class I major histocompatibility complex (MHC) molecule HLA-B27 and the CD8+ T cells associated with fibrocartilage. The exact role of the HLA-B27 in AS remains unknown, yet three theories of inflammatory function are currently held. HLA-B27, present on all nucleated somatic cells, functions as a membrane surface protein that induces a protective lysis response against identified foreign pathogens (Jethwa & Bowness, 2016). This occurs after HLA-B27 presents an intracellularly processed antigenic peptide to a CD8+ T cell to initiate an immune response toward the infective agents. The first theory of HLA-B27 involvement in AS focuses on the proposed cross-reactivity between HLA-B27 and host cell membrane peptides that occasionally occurs. For unknown reasons, HLA-B27’s inability to recognize certain host cells as “self” induces an immune response on these cells of the host tissue rather than the invading microorganisms themselves, thus

giving rise to an auto-immune pathology. When HLA-B27 reacts to self-antigens in this dysfunctional manner, the peptide can be classified as arthritogenic as it initiates an undue inflammatory response. The second theory states that genetically mutated HLA surface peptides induce an intracellular inflammatory response within its leukocyte's endoplasmic reticulum (ER) (the organelle in which protein synthesis and folding occurs). The final theory suggests that the innate immune system targets misfolded HLA proteins and destroys them through an inflammatory response (Jethwa & Bowness, 2016). Leukocyte presentation of mutated HLA-B27 in AS may induce their own destruction as immune cells, particularly natural killer (NK) cells, target the HLA-B27 homodimer with the killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2); Chan et al. found that patients with spondyloarthritic and enthesitis-related arthritic diseases have elevated expression of CD41+ T cells and the KIR3DL2 receptor on NK cells (Chan, Kollnberger, Wedderburn, & Bowness, 2005). Localized inflammation upon HLA-B27 homodimer and KIR3DL2-containing cell binding occurs through the T helper cell production of interleukin 17 (IL-17; a pro-inflammatory cytokine induced by IL-23). Increased numbers of these KIR3DL2 associated cells and a raised concentration of IL-17 were collected from the synovial fluid of spondyloarthritic patients while in AS specifically, a raised number of IL-17 associated immune cells were isolated from the spinal facet joints (Appel et al., 2011).

Research conducted with identical twins concludes this relationship between AS and HLA-B27 cannot be the only cause of AS; other genes outside the HLA coding region can be collectively responsible for disease development. Nearly 5-10% of patients

diagnosed with AS are HLA-B27 negative, which suggests that multiple mutations collectively cause the disease. As of 2016, Ellinghaus et al. presented AS as genetically linked to Crohn's disease (CD), primary sclerosing cholangitis (PSC), psoriasis (PS), and ulcerative colitis (UC) and thus expresses a high rate of comorbidity with these other autoimmune diseases. Ellinghaus et al. concluded the significant association of AS and these disorders are due to pleiotropy (one gene or gene affecting multiple phenotypic conditions), supported by their finding of 166 related, genome-spanning loci not associated with major histocompatibility complex (MHC) gene regions (Ellinghaus et al., 2016). These AS related loci were determined to mainly affect natural killer (NK) cells, CD34+ bone marrow cells, and undifferentiated immune cells by altering regulatory immune response pathways and the hematopoietic system. Typical T cells found in AS patients tend to secrete abnormally lower levels of tumor necrosis factor  $\alpha$  (TNF $\alpha$ ), a pro-inflammatory cytokine used to signal the destruction of pathogens and tumor cells by immune cells, and IL-10, a regulatory cytokine that facilitates the extent of an immune response by managing the concentrations of several pro-inflammatory cytokines (Sieper et al., 2002). A deficiency in these particular cytokines often prevents effective innate inflammatory responses against viral and bacterial pathogens which leads to either serial or chronic infections. With continued exposure to these viral or bacterial antigens, the risk of cross-reactivity between adaptive immune cells and continuously infected tissue increases greatly and may lead to development of autoimmune diseases (Sieper et al., 2002). Other such environmental factors like an altered microbiome within the gut and exposure to certain toxins or drugs can also collectively lead to the pathogenesis of AS

(Jethwa & Bowness, 2016). Overall genetically, AS appears to require multiple gene mutations for an active disease state with HLA-B27 taking about 30% of the genetic threat. Mutations within the respective genes that code for endoplasmic reticulum aminopeptidase 1 (ERAP1) (an ER enzyme that packages peptides, including HLA-B27, for surface presentation), the IL-23 receptor (IL-23R), and other genes associated with the IL-17/IL-23 pathway follow HLA-B27 in prevalence (Jethwa & Bowness, 2016).

The most recent pathological research conducted in regard to autoinflammatory diseases like AS focuses on the IL-17/IL-23 pathway. T helper 17 (Th17) cells stem from the regulatory branch of the helper T cell family and are notable for their IL-17 production and maintenance of mucosal barrier integrity through pathogen destruction. Decreased or mutated Th17 populations have been connected to chronic inflammatory states, dysregulation of healthy gut microbiomes that allow pathogenic colonization, and often autoimmunity (Hartigan-O'Connor, Hirao, McCune, & Dandekar, 2011). Sherlock et al.'s 2012 research involving murine models indicated that extrinsically introduced IL-23 to healthy mice facilitated the development of symptoms associated with spondyloarthritis. This phenotype occurred through IL-23 action toward various T cells receptors, namely IL-23R which induced a fairly instantaneous inflammatory response in local enthesis tissue without additional immune involvement, and caused increased production of pro-inflammatory cytokines, especially IL-17, along with other chemokines for later innate and adaptive immune responses (Sherlock et al., 2012). Autoinflammatory responses within the enthesis were assumed to be mediated by IL-17 associated immune cells without regulatory capability because Th17 cells were not isolated from localized

enthesitis inflammation (Appel et al., 2011). Increased concentrations of IL-23 producing cells, as well as elevated IL-17 and IL-23 serum concentrations, have been isolated from AS+ subchondral bone marrow and synovial fluid when compared to healthy patients (Davidson et al., 2011). More research regarding IL-23's mediation of Th17 cytokines and their subsequent inflammatory response should be conducted to further clarify the pathway depicted in Figure 3 and better understand its association with AS pathology.



*Figure 3.* Extended pathway of interleukin (IL)-17 and IL-23 (Jethwa & Bowness, 2016).

## **Physiology**

### **Cardiovascular Physiology**

AS manifests itself in different ways over the course of a patient's life, affecting the cardiovascular (CV), musculoskeletal, and neurological systems in detrimental ways. Certain serum protein levels are quite abnormal for AS patients. Increased levels of fibrinogen (a glycoprotein that aids in blood clot formation), IL-6 (a pro-inflammatory cytokine), and C-reactive protein (CRP; a protein used to indicate levels of inflammation in the body as it binds to phospholipids of damaged cells to initiate the innate immune

system response through the complement pathway) raise the viscosity of blood, which increases its likelihood to clot and mount a defense against self-antigens throughout the spine, entheses, peripheral joints, and other AS manifestation areas. These higher protein concentrations raise the erythrocyte sedimentation rate (ESR) which also increases the viscosity of the blood. AS patients are more likely to suffer from strokes and myocardial infarctions (MI) since blood clots form more readily and the arteries tend to be coated with fatty plaques. For unknown reasons, AS patients present with decreased levels of triglycerides and total body cholesterol, especially high density lipoproteins (HDLs) which regulate plaque formation in the arteries. This decrease in HDL leads to a greater prevalence of atherosclerosis in AS patients; these patients are twice as likely to experience strokes and MIs compared to healthy individuals (Park et al., 2012).

As the disease progresses, AS patients undergo an abnormal thickening of their mitral and aortic valves as marks of high blood pressure and continual systematic inflammation. Along with thickening of the heart valves, the thickening of the intima-media (innermost layer of an artery wall), especially within the carotid arteries, increases significantly with age (Mathieu, Gossec, Dougados, & Soubrier, 2011). These heart valve changes most likely occur after disease onset without noticeable effects to the patient (Park et al., 2012). Usten et al. measured left ventricular systolic function in AS patients with highly sensitive speckle tracking echocardiography (STE) rather than the commonly used conventional and Doppler echocardiography (ECG) techniques. Both the conventional and Doppler ECG machines are incapable of detecting minor ventricular dysfunctions (Ustun et al., 2015). The use of STE quantified significantly lower left

ventricular systolic and diastolic strain measurements with all STE parameters in AS patients compared to controls. These findings indicated weakened overall function of the left ventricle possibly due to systemic inflammation that damages cardiomyocytes (muscle cells of the heart) over the course of the disease.

### **Musculoskeletal Physiology**

As previously discussed, AS mainly debilitates the skeletal system at its cartilaginous sites like the spinal joints (articulating its superior and inferior vertebra and lateral ribs), the peripheral joints, and the entheses throughout the spine and other individually symptomatic areas. Activated immune cells targeting AS-associated self-antigens break down cartilaginous fibers of joints and entheses until the damaged tissues begin to ossify, producing new bone tissue in the place of flexible attachment sites for tendons, ligaments, and fascia. Ossified joints and entheses result in decreased mobility. Original flexibility diminishes, reducing physical strength and increasing AS-associated back and joint pain particularly during sedentary periods. As stated earlier, complete fusion of vertebral bones may occur in the axial spine when the outer linings of the intervertebral disks begin to ossify, creating what is known as “bamboo spine.” Fused spines like this fracture easily under trivial traumas, like bumping into a stranger, and heal poorly; they lack stability and durability as the disease progresses and greatly increase neurological complications during serious traumas involving the cervical spine (Westerveld et al., 2009). A prematurely stiff or nearly fused spine also constricts expansion of the rib cage which restricts airflow into the lungs below a normal level (McBride, King, Baikie, Crean, & Sircus, 1963). A constricted rib cage raises stress on

the pulmonary and CV systems, leading to reduced oxygen intake and increased heart rate that accounts for the structural changes in the heart and arteries.

### **Neurological Physiology**

The autoinflammatory nature of AS alters proper function of both the central nervous system (CNS; neurons associated with the brain and spinal cord) and the peripheral nervous system (PNS; neurons outside the CNS). The hypothalamic-pituitary-adrenal (HPA) axis is comprised of three separate endocrine organs that together regulate and counteract stress, immune responses, emotions, and metabolic expenditure. When tested in AS patients via the standard insulin tolerance test (ITT), the HPA axis will present normally when compared to control subjects, unlike similar rheumatic diseases like rheumatoid arthritis (RA) (Kirnap et al., 2008). A statistically insignificant, mild decrease in adrenal function was noted in tested AS subjects based on their abnormally lower basal cortisol levels prior to ITT testing. These results were possibly attributed to patients' previous NSAID treatments or how increased levels of pro-inflammatory cytokines, mainly IL-1, IL-6, and TNF $\alpha$ , appeared to raise adrenocorticotrophic hormone (ACTH) levels through modifying the effects of corticotrophin-releasing factor (Imrich et al., 2004). Further dynamic testing indicated no significant adrenal malfunction was present with AS patients (Kirnap et al., 2008).

Although the hypothalamus and pituitary gland appear unchanged within the AS brain, other networks of the brain involving attention, executive control, and somato-sensory function restructure with the course of the disease and communicate poorly. Significant reported fatigue in AS patients was inversely correlated with quantified spinal

mobility and emotional stamina; gray matter (neuronal bodies of the CNS associated with sensory perception, emotions, and decision-making capabilities) within the attention networks, somatosensory cortices (areas of the cerebrum that facilitate thoughts and perceptions into physical actions), and caudate nucleus (segment of brain that assists regulating goal-directed actions, memory, learning, and attention stabilization) were also negatively correlated with fatigue scores (Wu, Inman, & Davis, 2014). This indicates that AS patients experiencing an active disease state often have difficulty processing external stimuli appropriately and accomplishing higher cognitive goals. AS patients also tend to endure continuous neuropathic pain (perceived pain associated with malfunctioning of the somatosensory nervous system rather than damaged tissue) in which atrophy of gray matter in the aforementioned brain regions generally leads to poor control of the limbic system (midbrain regulator of emotions) and pain modulating centers (Wu, Inman, & Davis, 2013). AS neuropathic pain usually involves “shooting” or “stabbing” pain in individual problem areas along with dull, achy soreness associated back pain stemming from inflammation surrounding spinal nerves.

### **Diagnosis**

Historically, the concept and manifestations of AS were poorly understood by physicians until the mid-1900s. The first AS-focused studies associated the disease with other forms of inflammatory arthritic diseases like psoriatic arthritis, rheumatoid arthritis, Reiter’s disease, and inflammatory bowel disease (Sieper et al., 2002). By 1991, the clinical grouping of the aforementioned spondylarthropathies (SpAs) was modified by the European Spondylarthropathy Study Group (ESSG) to allow for more distinctive

diagnoses between the diseases (Dougados et al., 1991). All these auto-immune disorders share common symptoms like arthritic joint pain, stiffness, and the like although their immunological mechanisms are not identical because they often require different treatments. A proper ankylosing spondylitis diagnosis requires a patient to fall within a younger adult age set and present with a specific combination of symptoms within a designated time constraint for the onset of severe symptoms. These AS diagnosis qualifications were detailed in the *New York Criteria for Ankylosing Spondylitis* published in 1973 and act as the current standardized basis for scientists diagnosing research participants before undergoing any AS studies.

In the early 1960s, the minimum requirements for an AS diagnosis were “bilateral loss of definition or irregularity of the sacro-iliac spaces with subchondral sclerosis” (McBride et al., 1963). No discussion of the ankylosis of the cervical spine or accessory symptoms (like the now hallmark uveitis and enthesitis) occurred, which left this diagnostic system incomplete and unable to differentiate between multiple SpAs. A more complete evaluation of AS symptoms was compiled in the original 1973 New York Criteria diagnostic list as follows: 1) low back pain and stiffness lasting more than 3 months that is not alleviated by rest, 2) pain and stiffness in the thoracic region, 3) limited motion of the lumbar spine, 4) limited chest expansion, 5) history of iritis or its sequelae, and 6) x-rays showing bilateral sacroiliac changes characteristic with ankylosing spondylitis (excluding bilateral osteoarthritis of the sacroiliac joints) (Moll & Wright, 1973). Over the years, the need for a more comprehensive diagnostic system grew with the collection of additional pathological and physiological information about AS;


multiple researchers then modified the New York criteria to include extra differential symptoms and characteristics of the current patient population seen in Table 1. Calin et al. made additional requirements of “AS onset before age 40” and the “onset of disease is insidious in nature” to better match the data of his sample and review populations (Calin, Porta, Fries, & Schurman, 1977).

Table 1. *Modified Criteria for Ankylosing Spondylitis (Sieper et al., 2002).*

<b>Radiologic criterion</b>
Sacroiliitis, grade $\geq$ II bilaterally or grade III to IV unilaterally
<b>Clinical criteria</b>
Low back pain and stiffness for more than 3 months that improves with exercise that is not relieved by rest
Limitation of motion of the lumbar spine in both the sagittal and frontal planes
Limitation of chest expansion relative to normal values correlated for age and sex

Note: *The condition is definitely AS if the radiological criterion is associated with at least 1 clinical criterion.*

Physicians analyze a patient’s symptoms with the previously mentioned criteria in mind to monitor alignment of symptoms with an AS diagnosis using a diagnostic algorithm, seen in Figure 3.



*Figure 3.* Diagnostic algorithm for axial SpA (early AS) starting with the assessment of inflammatory back pain (Sieper et al., 2002).

Confirmed symptoms farther down the pyramid of Figure 1 carry more diagnostic weight than those near the top due to the narrowly direct association with the disease. Accessory symptoms to inflammatory arthritis of the axial skeleton include enthesitis (inflammation of the enthesis that joins bone to collagen fibers of tendons, ligaments, and fascias), uveitis (inflammation of ovea, the middle layer of the eye), asymmetric arthritis of the peripheral joints, family history of the disease, a confirmed HLA-B27 gene mutation, raised C-reactive protein levels in the blood (CRP), and a positive response to NSAIDs. At least two of these accessory symptoms must be present in addition to spondylitis and radiographic evidence of sacroiliitis for an AS diagnosis to be made. A positive HLA-B27 genetic test is one of the strongest indicators of active AS. 90-95% of those diagnosed with the disease also have a mutation within an HLA-B27 coding region (Sieper et al., 2002).

Upon diagnosis, physicians have often incorporated the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as a functional scale to measure the severity of a patient's disease and provide quantitative data regarding the efficacy of a newly applied treatment. The BASDAI reliably compiles a scaling of six major AS complaints: 1) fatigue severity; 2) pain in spinal joints; 3) swelling and pain in peripheral joints; 4) enthesitis severity (worded as "localized tenderness"); 5) duration of morning stiffness; and 6) severity of morning stiffness (Li et al., 2016). Patients can quickly record their personal evaluation of each symptom with a 1-10 scale (1 indicating no issue and 10 indicating the severest issue) in which each of the first four symptoms are given equal weight with the averaged morning stiffness symptom scales. This creates a 0-50 scale that is then divided by 5 for an official 0-10 BASDAI score used to rank and compare total AS severity among patients (Chung, Lau, Wu, Wong, & Mok, 2011). A BASDAI score of 4 or greater indicates poor disease management; these patients are prime candidates for altering their present treatment, possibly to include a biologic medication like a TNF $\alpha$  antibody. Clinical researchers use the BASDAI to identify appropriate candidates for new drug trials geared toward slowing AS progression and measure the success of the treatment. Aside from the BASDAI, other disease scoring tests specifically for AS are commonly used, such as Bath Ankylosing Spondylitis Metrology Index (BASMI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS), though the BASDAI is considered the "gold standard" for AS disease scoring (Zochling, 2011).

## **Treatments**

### **Prior Treatments**

The advancements in treating AS have become safer, more comprehensive, and more effective since the early 1900s. Before the 1950s, physicians attempted to treat AS symptoms with several rounds of x-ray therapy over the course of several months. The theorized goal of this therapy was to stimulate hormones that were presumably unbalanced to induce mast cells release of their higher concentration of sulfur. At the time, researchers believed mast cells, as well as other leukocytes, carrying more sulfur than usual absorbed it from cartilaginous fibers surrounding the sacroiliac joints, thus damaging the cartilage which would then heal as bone tissue: the proposed etiological origin of AS (Tegner, 1946). A more involved understanding of the immune system as a whole and its specific relationship with AS proved this prior theory false. Although x-ray therapy relieved pain in treated patients, this now controversial treatment plays no role in preventing disease development today. No changes in bone sedimentation of inflamed joints or radiographic evidence of spinal damage were noted during the course of x-ray therapy, so the treatment was deemed ineffective in controlling the progression of AS. Even though the continual exposure to x-rays decreased a patient's pain, the treatment was discontinued throughout the United States when further research indicated that increased rates of cancer in AS patients stemmed from the carcinogenic therapy.

### **Non-pharmacological Treatment**

One treatment doctors have reached a consensus on is the incorporation of physical activity into the daily lives of AS patients. Research finds that individuals with

AS who held a consistent exercise program over 4 months increased the function of their spine and peripheral joints significantly compared to sedentary AS patients (Zochling, van der Heijde, Dougados, & Braun, 2006). This study conducted by Zochling et al. (2006) compared the exercises prescribed and supervised by a licensed physical therapist to patient organized daily movement at home to see if one particular regime decreased AS stiffness and pain more than the other. Zochling et al. concluded that neither regime was more effective than the other; simply moving the joints and raising the heart rate consistently alleviates much of the symptomatic stiffness. They also found that while exercise decreased the patients' overall stiffness, their subjective levels of pain remained relatively the same as before exercise. Impact exercises, such as running and contact sports, are high risk activities for patients with active AS. Jarring movements associated with these exercises cause additional stress on the joints and spine an AS patient is unable to heal properly since damaged fibrocartilage is mistakenly converted into bone tissue, increasing the risk that injury could hasten the rate of disease progression (Zochling et al., 2006). Impact sports could potentially fracture a delicate, ankylosed spine which may not heal to regain functionality. Non-impact physical activities like bike riding, swimming, yoga, and gentle power walking are highly recommended exercise alternatives for AS patients.

Other recommended non-pharmacological lifestyle changes for AS include educating patients concerning their disease, its treatments, and daily restrictions; drinking alcoholic beverages in moderation; avoiding smoking and using recreational drugs; remaining hydrated throughout the day; eating a diet low in starches and sugars, possibly

adhering to a gluten-free and sugar-conscious diet, to avoid disease flare ups; and committing to an appropriate sleeping regimen that includes at least 7 hours of sleep per night (Zochling et al., 2006). Since an abnormal sleep schedule may further aggravate the chronic inflammatory state, patients are recommended to adopt consistent sleeping habits as newer research correlates adequate sleep with possible disease remission (Leverment, Clarke, Wadeley, & Sengupta, 2017). The maintenance of mental health is also especially important. Emotional stress left unchecked in an AS patient has the potential to increase the diagnosis of depressive and anxiety disorders, along with a heightened level of disease related pain. In a state of depression and anxiety, patients may be mentally unable to complete their treatment of AS by remaining isolated and sedentary within their homes, possibly avoiding exercise, increasing or decreasing eating, sleeping too much or too little, and taking their medications in ways other than as prescribed. Patients experiencing symptoms of depression along with their AS diagnosis should seek help from a medical professional, either their general care doctors or a psychiatrist, and a licensed counselor to discover the cause of these psychological concerns (Basler & Rehfisch, 1991).

### **Non-steroidal Anti-inflammatory Drugs (NSAIDs)**

NSAIDs are considered the cornerstone of AS therapy; NSAIDs are the cheapest and longest studied drugs used to treat ankylosing spondylitis. These drugs exhibit analgesic (relief from pain) and antipyretic (reduction of fever) properties by inhibiting cyclooxygenase 1 and 2 (COX-1 and COX-2), enzymes that assist in antibody synthesis and catalyze prostaglandins that regulate several physiological responses during local and

systemic inflammation (Bancos, Bernard, Topham, & Phipps, 2009). NSAIDs also clinically modify multiple other branches of the innate and adaptive immune system through the reduction of T lymphocyte activation and proliferation, monocyte activation, cytokine production, and formation of leukotrienes.

Diclofenac, the most prescribed NSAID for AS, has been found effective and safe in treating AS in long-term cases and short-term flare ups (Calabro, 1986). Typically, 75mg of diclofenac twice daily is enough to provide a therapeutic effect to treat predominantly axial manifestations of the disease as well as peripheral joint arthritis and enthesitis. Though the half-life of diclofenac lasts about an hour or two, the drug continues to work actively in synovial fluid for up to 11 hours (Small, 1989). 200mg daily of celecoxib, another commonly prescribed NSAID for AS patients, has the same efficacy of treatment as diclofenac with fewer adverse gastrointestinal side effects (Sieper et al., 2008). The mechanism of action for NSAIDs indirectly weakens the epithelium of the stomach by the reduction of prostaglandin production, leading to the main adverse effect of NSAIDs: stomach ulcers and increased sensitivity to gastric acid corrosion. Since NSAIDs have long been the premier treatment of AS, a patient must undergo two failed NSAID trials before a presiding rheumatologist considers alternative treatments to include tumor necrosis factor- $\alpha$  (TNF $\alpha$ ) blockers, discussed later in this review.

### **Disease-modifying Antirheumatic Drugs (DMARDs)**

Low doses of DMARDs are also considered safe, first action drugs for AS. Anti-malarial drugs, gold salts, various immunosuppressants, and methotrexate can be incorporated into auto-immune disease treatment in general, with methotrexate as the

chief drug of the list to treat AS. Overall, normal AS patients tolerate DMARDs well with few serious side effects. (Pregnant patients should avoid methotrexate since the drug acts as an abortifacient; patients fighting an infection should avoid penicillins because the two drugs combined can lead to a fatal reaction.) Methotrexate's method of action inhibits the metabolism of folic acid, then inhibiting the activation of T cells by suppressing the intercellular adhesion molecules between T cells, causing B cells to selectively down-regulate, and inhibiting interleukin 1  $\beta$  cell surface receptors to effectively decrease the immune responses capable of damaging an AS patient's joints and entheses (Chen, Veras, Liu, & Lin, 2013). Research finds that a 12.5mg intramuscular injection of methotrexate once-weekly is effective to treat morning stiffness, disease intensity, and axial and peripheral joint functionality in older AS patients and patients in a later disease state. The state of disease progression can be physically viewed through radiographic imaging of the sacroiliac joints as well as recording the range of mobility in affected joints using a goniometer. Methotrexate is often synergistically paired with infliximab, a TNF $\alpha$  blocker, to treat cases of AS ineffectively reduced by NSAIDs use. Methotrexate and other DMARDs should not be paired with NSAIDs; the combination of the drugs could cause a potentially fatal reaction (Chen et al., 2013).

### **Monoclonal TNF $\alpha$ Antibodies**

TNF $\alpha$  is presumed to be a pivotal cytokine in AS pathogenesis; TNF $\alpha$  and other cytokines in its cascade pathway can be consistently collected from the synovial fluid, serum, and sacroiliac joints of patients in an active disease state (Gorman, Sack, & Davis,

2002). Anti-TNF $\alpha$  drugs, usually a monoclonal human antibody, have proven some of the most effective drugs at treating spinal structures and peripheral entheses and preventing disease progression, which can be viewed via radiographic evidence. Extended treatment with anti-TNF $\alpha$  antibodies induces an immunosuppressive state in which the patient is more susceptible to illnesses like tuberculosis, influenza, and certain types of cancers, but many physicians believe the benefits of the drug sharply outweigh the risks of further illness. Three anti-TNF $\alpha$  agents are currently approved for use in the US and the UK: infliximab, etanercept, and adalimumab which are sold under the trade names Remicade, Enbrel, and Humira, respectively. Normally paired with a methotrexate drug, infliximab is a monoclonal antibody that binds up TNF $\alpha$  and is infused intravenously over 1-2 hours every 8 weeks (Braun et al., 2003). Etanercept is a small molecule that competes for the TNF- $\alpha$  receptor on cell surfaces, administered to patients in 25mg increments via subcutaneous injection twice weekly (Braun et al., 2003). The last anti-TNF $\alpha$  drug, adalimumab, is a 40mg portion of a monoclonal human anti-TNF $\alpha$  antibody injected subcutaneously biweekly. Even from the limited studies concerning the newly developed technology, researchers have concluded that these three anti-TNF $\alpha$  drugs, especially adalimumab, possess an extremely high efficacy in treating AS.

Since these drugs were only recently developed, long term effects on organs and their systems are currently unknown and the cost of production remains extremely expensive, with the retail price costing upwards of \$1000 US per injection. Anti-TNF $\alpha$  antibodies have also been linked to new cancer diagnoses, especially lymphomas, following continued drug administration. Doctors and insurance companies try to reserve

these costly medicines for those with the most severe cases of AS that cannot be controlled through other methods. Requirements for a TNF $\alpha$  blocker prescription include 1) a diagnosis of AS according to the New York criteria previously described (including radiographic evidence of sacroiliitis); 2) failure of at least 2 adequate trials of NSAID therapy; 3) persistence and worsening of disease activity; 4) threat of severe damage from disease; and 5) likelihood of response to a TNF $\alpha$  blocker as determined by the rheumatologist. Once a patient's conditions expresses these five conditions, a presiding doctor can then prescribe one of the three drugs. If patients become actively diagnosed with certain autoimmune disorders, infection, malignancy, or becomes pregnant, they are disqualified from receiving TNF $\alpha$  blockers. Due to the potential cancerous side effects, high cost, and high efficacy of the TNF $\alpha$  blocker drugs, doctors recommend infliximab, etanercept, and adalimumab be taken in 6-12-week intervals after which the monitoring physician assesses the level of disease improvement. If less than 50% relative improvement occurs during the 6-12-week time period, the patient continues taking the drug through the next period. If a patient experiences a relative improvement greater than 50%, the drug is discontinued during the next 6-12 week interval until the patient begins to deteriorate again (Braun et al., 2003).

### **Proposed Therapies**

Currently, no other biologic treatments specifically approved for AS are available to patients beside TNF $\alpha$  blockers. New, promising research involving the treatment of plaque psoriasis, a dermatological autoimmune disease genetically linked to AS, with biologic drugs ixekizumab, secukinumab, and ustekinumab (respective trade names:

Taltz, Cosentyx, and Stelara; respective market release: 2016, 2015, and 2013) could lead to possible treatments for AS (Ellinghaus et al., 2016). Ixekizumab and secukinumab are both monoclonal antibodies that target IL-17 cytokines within the IL-23-T helper 17 pathway. According to Gomez-Garcia et al. (2016), both drugs were found more efficacious in treating plaque psoriasis in Japanese patients than TNF $\alpha$  monoclonal antibodies in short-term therapy yet both were more likely to lead to drug complications: infliximab use increased the risk for adverse effects (AE) other than infections while secukinumab increased patients' susceptibility to infection (Gomez-Garcia et al., 2016). Ustekinumab, a monoclonal antibody that binds to the shared protein subunit between IL-12 and IL-23, also exhibited significant efficacy in treating plaque psoriasis in the aforementioned study. Ustekinumab presented as the highest ranked efficacy-safety profiled drug tested by Gomez-Garcia et al. (2016), including ixekizumab, secukinumab, and popular TNF $\alpha$  antibodies, namely etanercept and adalimumab (Gomez-Garcia et al., 2016). Brodalumab is a monoclonal antibody not yet approved by the Food and Drug Administration (FDA) that functions as a competitive inhibitor for the IL-17A receptor that showed promise in treating plaque psoriasis effectively (Nakagawa, Niuro, Ootaki, & Japanese brodalumab study, 2016). These biologic drugs that prove effective in treating psoriatic patients should be further investigated especially in regard to possible treatment of AS. Preliminary research to understand the IL-23/IL-17 pathway in AS pathogenesis is currently underway in hopes of leading to clinical trials involving the aforementioned drugs (Jethwa & Bowness, 2016).

Ankylosing spondylitis is an auto-inflammatory disorder that targets cellular surface molecules associated with fibrocartilage within entheses throughout the body, mainly within the axial spine, resulting in reduced patient mobility and quality of life. Cross-reactive immune cells, often expressing an allotype of HLA-B27 with the abnormal ability to present self-antigens, illicit damage at these fibrocartilaginous sites before the tissue heals as bone. Extensive deposition of bone in these tissues may produce the “bamboo spine” characteristic to AS. Since the aforementioned cross-reactive immune cells have constant access to their fibrocartilaginous auto-antigens, the body experiences a state of chronic inflammation perpetuated in part by the IL-17/IL-23 cytokine pathway. Adverse cardiovascular and neurological effects associated with AS stem from generalized chronically activated immune and chronic pain states, respectively, while the musculoskeletal effects are more exclusive to the specific disease. Proper diagnosis requires simultaneous presentation of multiple symptoms including, but not limited to, insidious onset of back pain and stiffness lasting more than 3 months, limited expansion of the ribcage, a positive response to NSAIDs, a positive test for HLA-B27 mutation, peripheral arthritis, uveitis, enthesitis, and radiologic evidence of sacroiliitis. Upon diagnosis, several courses of treatment exist for AS patients ranging from healthy lifestyle changes to immunosuppressant antibody drugs. General practitioners and rheumatologists recommend their AS patients avoid high-impact exercise, smoking, the consumption of alcoholic beverages, gluten-based food products, and irregular sleeping habits. Patients are encouraged to educate themselves regarding their disease limitations in addition to preserving their mental health and partaking in

core-strengthening exercises. More severe cases of AS often require pharmaceutical intervention with a combination of NSAIDs, DMARDs, and anti-TNF $\alpha$  antibodies, all of which should depress the overactive immune system response for symptom relief and slow disease progression. Each class of drug has its own list of benefits and drawbacks that should be considered in totality prior to creating a patient's treatment plan.

## References

- Appel, H., Maier, R., Wu, P., Scheer, R., Hempfing, A., Kayser, R., . . . Sieper, J. (2011). Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. *Arthritis Res Ther*, *13*(3), R95. doi:10.1186/ar3370
- Bancos, S., Bernard, M. P., Topham, D. J., & Phipps, R. P. (2009). Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. *Cell Immunol*, *258*(1), 18-28. doi:10.1016/j.cellimm.2009.03.007
- Basler, H. D., & Rehfisch, H. P. (1991). Cognitive-behavioral therapy in patients with ankylosing spondylitis in a German self-help organization. *J Psychosom Res*, *35*(2-3), 345-354.
- Braun, J., Pham, T., Sieper, J., Davis, J., van der Linden, S., Dougados, M., . . . Group, A. W. (2003). International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. *Ann Rheum Dis*, *62*(9), 817-824.
- Calabro, J. J. (1986). Efficacy of diclofenac in ankylosing spondylitis. *Am J Med*, *80*(4B), 58-63.
- Calin, A. (1984). Comment on van der Linden article. *Arthritis Rheum*, *27*(12), 1438.
- Calin, A., Porta, J., Fries, J. F., & Schurman, D. J. (1977). Clinical history as a screening test for ankylosing spondylitis. *JAMA*, *237*(24), 2613-2614.

- Chan, A. T., Kollnberger, S. D., Wedderburn, L. R., & Bowness, P. (2005). Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. *Arthritis Rheum*, 52(11), 3586-3595. doi:10.1002/art.21395
- Chen, J., Veras, M. M., Liu, C., & Lin, J. (2013). Methotrexate for ankylosing spondylitis. *Cochrane Database Syst Rev*, 2, CD004524. doi:10.1002/14651858.CD004524.pub4
- Chung, H. Y., Lau, C. S., Wu, K. P., Wong, W. S., & Mok, M. Y. (2011). Comparison of performance of the Assessment of SpondyloArthritis International Society, the European Spondyloarthropathy Study Group and the modified New York criteria in a cohort of Chinese patients with spondyloarthritis. *Clin Rheumatol*, 30(7), 947-953. doi:10.1007/s10067-011-1693-6
- Davidson, S. I., Liu, Y., Danoy, P. A., Wu, X., Thomas, G. P., Jiang, L., . . . Xu, H. (2011). Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese. *Ann Rheum Dis*, 70(2), 289-292. doi:10.1136/ard.2010.133322
- Dougados, M., van der Linden, S., Juhlin, R., Huitfeldt, B., Amor, B., Calin, A., . . . et al. (1991). The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. *Arthritis Rheum*, 34(10), 1218-1227.
- Ellinghaus, D., Jostins, L., Spain, S. L., Cortes, A., Bethune, J., Han, B., . . . Franke, A. (2016). Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. *Nat Genet*, 48(5), 510-518. doi:10.1038/ng.3528

- Gomez-Garcia, F., Epstein, D., Isla-Tejera, B., Lorente, A., Velez Garcia-Nieto, A., & Ruano, J. (2016). Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. *Br J Dermatol*, *176*(3), 594-603. doi:10.1111/bjd.14814
- Gorman, J. D., Sack, K. E., & Davis, J. C., Jr. (2002). Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. *N Engl J Med*, *346*(18), 1349-1356. doi:10.1056/NEJMoa012664
- Hartigan-O'Connor, D. J., Hirao, L. A., McCune, J. M., & Dandekar, S. (2011). Th17 cells and regulatory T cells in elite control over HIV and SIV. *Curr Opin HIV AIDS*, *6*(3), 221-227. doi:10.1097/COH.0b013e32834577b3
- Imrich, R., Rovensky, J., Zlnay, M., Radikova, Z., Macho, L., Vigas, M., & Koska, J. (2004). Hypothalamic-pituitary-adrenal axis function in ankylosing spondylitis. *Ann Rheum Dis*, *63*(6), 671-674. doi:10.1136/ard.2003.006940
- Jamshidi, A. R., Shahlaee, A., Farhadi, E., Fallahi, S., Nicknam, M. H., Bidad, K., . . . Mahmoudi, M. (2014). Clinical characteristics and medical management of Iranian patients with ankylosing spondylitis. *Mod Rheumatol*, *24*(3), 499-504. doi:10.3109/14397595.2013.844302
- Jethwa, H., & Bowness, P. (2016). The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment. *Clin Exp Immunol*, *183*(1), 30-36. doi:10.1111/cei.12670

- Kirnap, M., Atmaca, H., Tanriverdi, F., Ozsoy, O., Unluhizarci, K., & Kelestimur, F. (2008). Hypothalamic-pituitary-adrenal axis in patients with ankylosing spondylitis. *Hormones (Athens)*, 7(3), 255-258.
- Leverment, S., Clarke, E., Wadeley, A., & Sengupta, R. (2017). Prevalence and factors associated with disturbed sleep in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review. *Rheumatol Int*, 37(2), 257-271. doi:10.1007/s00296-016-3589-x
- Li, C., Wei, X., Zou, Q., Zhang, Y., Yin, X., Zhao, J., & Wang, J. (2016). Cerebral functional deficits in patients with ankylosing spondylitis- an fMRI study. *Brain Imaging Behav*, 1-7. doi:10.1007/s11682-016-9565-y
- Mathieu, S., Gossec, L., Dougados, M., & Soubrier, M. (2011). Cardiovascular profile in ankylosing spondylitis: A systematic review and meta-analysis. *Arthritis Care Res (Hoboken)*, 63(4), 557-563. doi:10.1002/acr.20364
- McBride, J. A., King, M. J., Baikie, A. G., Crean, G. P., & Sircus, W. (1963). Ankylosing Spondylitis and Chronic Inflammatory Diseases of the Intestines. *Br Med J*, 2(5355), 483-486.
- Moll, J. M., & Wright, V. (1973). New York clinical criteria for ankylosing spondylitis. A statistical evaluation. *Ann Rheum Dis*, 32(4), 354-363.
- Nakagawa, H., Niino, H., Ootaki, K., & Japanese brodalumab study, g. (2016). Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety

results from a phase II randomized controlled study. *J Dermatol Sci*, 81(1), 44-52.

doi:10.1016/j.jdermsci.2015.10.009

Park, S. H., Sohn, I. S., Joe, B. H., Hwang, H. J., Park, C. B., Jin, E. S., . . . Lee, S. H.

(2012). Early cardiac valvular changes in ankylosing spondylitis: A

transesophageal echocardiography study. *J Cardiovasc Ultrasound*, 20(1), 30-36.

doi:10.4250/jcu.2012.20.1.30

Sherlock, J. P., Joyce-Shaikh, B., Turner, S. P., Chao, C. C., Sathe, M., Grein, J., . . . Cua,

D. J. (2012). IL-23 induces spondyloarthropathy by acting on ROR-gammat+

CD3+CD4-CD8- enthesal resident T cells. *Nat Med*, 18(7), 1069-1076.

doi:10.1038/nm.2817

Sieper, J., Braun, J., Rudwaleit, M., Boonen, A., & Zink, A. (2002). Ankylosing

spondylitis: An overview. *Ann Rheum Dis*, 61 Suppl 3, iii8-18.

Sieper, J., Klopsch, T., Richter, M., Kapelle, A., Rudwaleit, M., Schwank, S., . . . May,

M. (2008). Comparison of two different dosages of celecoxib with diclofenac for

the treatment of active ankylosing spondylitis: Results of a 12-week randomised,

double-blind, controlled study. *Ann Rheum Dis*, 67(3), 323-329.

doi:10.1136/ard.2007.075309

Small, R. E. (1989). Diclofenac sodium. *Clin Pharm*, 8(8), 545-558.

Tegner, W. (1946). Ankylosing spondylitis; review. *Ann Rheum Dis*, 5, 103.

Ustun, N., Kurt, M., Nacar, A. B., Karateke, H. P., Guler, H., & Turhanoglu, A. D.

(2015). Left ventricular systolic dysfunction in patients with ankylosing

spondylitis without clinically overt cardiovascular disease by speckle tracking

echocardiography. *Rheumatol Int*, 35(4), 607-611. doi:10.1007/s00296-014-3130-

z

Westerveld, L. A., Verlaan, J. J., & Oner, F. C. (2009). Spinal fractures in patients with ankylosing spinal disorders: A systematic review of the literature on treatment, neurological status and complications. *Eur Spine J*, 18(2), 145-156.

doi:10.1007/s00586-008-0764-0

Wu, Q., Inman, R. D., & Davis, K. D. (2013). Neuropathic pain in ankylosing spondylitis: A psychophysics and brain imaging study. *Arthritis Rheum*, 65(6), 1494-1503. doi:10.1002/art.37920

Wu, Q., Inman, R. D., & Davis, K. D. (2014). Fatigue in ankylosing spondylitis is associated with the brain networks of sensory salience and attention. *Arthritis Rheumatol*, 66(2), 295-303. doi:10.1002/art.38244

Zochling, J. (2011). Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). *Arthritis Care Res (Hoboken)*, 63 Suppl 11, S47-58. doi:10.1002/acr.20575

Zochling, J., van der Heijde, D., Dougados, M., & Braun, J. (2006). Current evidence for the management of ankylosing spondylitis: A systematic literature review for the

ASAS/EULAR management recommendations in ankylosing spondylitis. *Ann*

*Rheum Dis*, 65(4), 423-432. doi:10.1136/ard.2005.041129